nivolumab,etigilimab
mereo biopharmaceuticalceutical,bms,marker therapeutics
['nivo', 'etigilimab', 'solid tumor', 'biomarker', 'nivolumab', 'marker ', 'mereo ', '$mreo']
mereo biopharma $mreo reports clinical update and interim biomarker analysis presented at esmo 2022 from activate phase 1b/2 open label study of etigilimab (anti-tigit antibody mph-313) plus nivolumab (anti-pd-1 antibody) in solid tumors 
Biotellytics / https://t.co/37itIfRolp = business intel service on listed European Bios / Views=mine only, RT-like=/=endorse, no advice. 16y in Tech (chip design)